New Jersey Court rules against Johnson & Johnson's 'Zytiga' Patent!

November 12,2018:

On 27th October 2018, a federal judge in New Jersey ruled against Johnson & Johnson's key Patent which protected their prostate-cancer drug called Zytiga.

Zytiga is one of Johnson & Johnson's best-selling drugs, and it has generated revenues in billions for the company.

Previously, Johnson & Johnson had sued several companies, which intended to copy the generic version of Zytiga and earned revenue. A few companies involved in this act included Dr. Reddy's Laboratories Ltd., Mylan and Teva Pharmaceutical Industries Ltd.

This decision is a win for generic-drug companies, but they are not allowed to launch their units until October 31 2018, as per the U.S. District Judge Kevin McNulty. The judge further said that he wants to maintain the status quo while considering whether to obstruct the generics until the point that an Appeals Court governs on the Patent.

Caroline Pavis, a spokeswoman for Johnson & Johnson’s Janssen unit said- "We strongly disagree with the court’s ruling and will continue to defend the patent," also we plan to appeal against the decision."

To Visit Website, Trademarkclick.com, Click Here